Indalo Therapeutics
Indalo Therapeutics is a biotech company in St. Louis, United States, founded in 2016. It has raised $26.0M across 1 round, most recently a $26.0M Series A in August 2017.
- Headquarters
- St. Louis, Missouri
- Founded
- 2016
- Business Model
- B2B
- Total Funding
- $26.0M
- Last Round
- $26.0M Series AAug 2017
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 3 investors for this company. The full record is or through the API.
About
Indalo Therapeutics is a St. Louis-based biopharmaceutical company formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. The company discovers and develops integrin antagonist therapies, including lead candidate IDL-2965, to treat serious fibrotic diseases such as idiopathic pulmonary fibrosis and NASH. Indalo has advanced its programs through Phase 1 clinical trials, backed by an experienced management team, strong intellectual property, and investors including Atlas Venture and F-Prime Capital.
Summary
It has raised $26.0M in total across 1 round, most recently a $26.0M Series A round in Aug 2017. Investors include Atlas Venture, F-Prime Capital and Missouri Technology Co.
Funding History
Aug 2017
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/indalo-therapeutics"><img src="https://indexed.vc/api/badge/company/indalo-therapeutics" alt="Indalo Therapeutics on Indexed.vc" width="260" height="76" /></a>